Black Diamond Therapeutics Says Initial Dose Escalation Data Demonstrates Anti-Tumor Activity Of BDTX-1535 In Non-small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families
Portfolio Pulse from Benzinga Newsdesk
Black Diamond Therapeutics announced initial dose escalation data showing anti-tumor activity of BDTX-1535 in non-small cell lung cancer patients across multiple EGFR mutation families.
June 27, 2023 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Black Diamond Therapeutics' BDTX-1535 demonstrates anti-tumor activity in non-small cell lung cancer patients, potentially boosting the company's stock.
The positive initial data for BDTX-1535 in non-small cell lung cancer patients indicates that the drug has potential in treating multiple EGFR mutation families. This could lead to increased investor interest and a potential boost in Black Diamond Therapeutics' stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100